Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
73
KPTI Quote, Financials, Valuation and Earnings
Last price:
$9.68
Seasonality move
:
-13.4%
Day range:
$9.14 - $9.82
52-week range:
$3.51 - $10.38
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.69x
P/B ratio:
--
Volume:
754.7K
Avg. volume:
611.4K
1-year change:
-2.12%
Market cap:
$169.7M
Revenue:
$146.1M
EPS (TTM):
-$16.62
Analysts' Opinion
-
Consensus RatingKaryopharm Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.33, Karyopharm Therapeutics, Inc. has an estimated upside of 65.77% from its current price of $9.25.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 35.14% downside risk from its current price of $9.25.
Fair Value
-
According to the consensus of 5 analysts, Karyopharm Therapeutics, Inc. has 65.77% upside to fair value with a price target of $15.33 per share.
KPTI vs. S&P 500
-
Over the past 5 trading days, Karyopharm Therapeutics, Inc. has overperformed the S&P 500 by 39.44% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Karyopharm Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Karyopharm Therapeutics, Inc. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Karyopharm Therapeutics, Inc. reported revenues of $34.1M.
Earnings Growth
-
Karyopharm Therapeutics, Inc. earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Karyopharm Therapeutics, Inc. reported earnings per share of -$5.71.
Enterprise value:
339.5M
EV / Invested capital:
-5.72x
Price / LTM sales:
0.69x
EV / EBIT:
--
EV / Revenue:
2.32x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-4.51x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$139.8M
Return On Assets:
-160.51%
Net Income Margin (TTM):
-134.21%
Return On Equity:
--
Return On Invested Capital:
-1579.24%
Operating Margin:
-52.36%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $146M | $145.2M | $146.1M | $30.5M | $34.1M | |
| Gross Profit | $140.6M | $138.9M | $139.8M | $29.1M | $32.6M | |
| Operating Income | -$129.5M | -$119.4M | -$90.7M | -$31.3M | -$17.8M | |
| EBITDA | -$129M | -$119.1M | -$90.4M | -$31.2M | -$17.8M | |
| Diluted EPS | -$1.25 | -$4.45 | -$16.62 | -$3.67 | -$5.71 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $275.6M | $350.2M | $233.9M | $156.5M | $103.1M | |
| Total Assets | $305.3M | $358.2M | $240.4M | $164.4M | $117.5M | |
| Current Liabilities | $73.7M | $65.9M | $69.5M | $92.3M | $92.1M | |
| Total Liabilities | $385M | $374.8M | $376.6M | $350.4M | $410.4M | |
| Total Equity | -$79.7M | -$16.7M | -$136.2M | -$186M | -$292.9M | |
| Total Debt | $178.3M | $176.2M | $173.7M | $194.1M | $232.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$92.7M | -$127.5M | -$75.4M | -$25.8M | -$11.8M | |
| Cash From Investing | $7.9M | $95.5M | $43.4M | $14.8M | $5M | |
| Cash From Financing | $1.1M | $41.6M | $30M | $680K | $29.7M | |
| Free Cash Flow | -$92.7M | -$127.6M | -$75.4M | -$25.8M | -$11.8M | |
KPTI
Sector
Market Cap
$169.7M
$25.8M
Price % of 52-Week High
89.11%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-12.9%
-1.67%
1-Year Price Total Return
-2.12%
-21.92%
Beta (5-Year)
0.208
0.499
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$7.84
200-day SMA
Buy
Level
$5.81
Bollinger Bands (100)
Buy
Level
5.6 - 7.36
Chaikin Money Flow
Sell
Level
-9.7M
20-day SMA
Buy
Level
$7.06
Relative Strength Index (RSI14)
Buy
Level
69.41
ADX Line
Buy
Level
24.48
Williams %R
Sell
Level
-17.0792
50-day SMA
Buy
Level
$7.05
MACD (12, 26)
Buy
Level
0.49
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
569K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-21.9669)
Sell
CA Score
(Annual)
Level (-13.0563)
Buy
Beneish M-Score
(Annual)
Level (-4.0869)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (23.3623)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.
Stock Forecast FAQ
In the current month, KPTI has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The KPTI average analyst price target in the past 3 months is $15.33.
-
Where Will Karyopharm Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Karyopharm Therapeutics, Inc. share price will rise to $15.33 per share over the next 12 months.
-
What Do Analysts Say About Karyopharm Therapeutics, Inc.?
Analysts are divided on their view about Karyopharm Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Karyopharm Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Karyopharm Therapeutics, Inc.'s Price Target?
The price target for Karyopharm Therapeutics, Inc. over the next 1-year time period is forecast to be $15.33 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is KPTI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Karyopharm Therapeutics, Inc. is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KPTI?
You can purchase shares of Karyopharm Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Karyopharm Therapeutics, Inc. shares.
-
What Is The Karyopharm Therapeutics, Inc. Share Price Today?
Karyopharm Therapeutics, Inc. was last trading at $9.68 per share. This represents the most recent stock quote for Karyopharm Therapeutics, Inc.. Yesterday, Karyopharm Therapeutics, Inc. closed at $9.25 per share.
-
How To Buy Karyopharm Therapeutics, Inc. Stock Online?
In order to purchase Karyopharm Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get KPTI Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KPTI
Sector
P/E ratio
--
23.35x
PEG ratio
0.00x
-0.01x
P/B ratio
--
1.78x
Price / LTM sales
0.69x
1.55x
Growth Metrics
KPTI
Sector
Revenue growth
11.58%
3.74%
Earnings growth
-55.63%
11.14%
Revenue (5-year growth)
6.21%
6.38%
Earnings forecast
-$2.00
-$0.19
Profitability
KPTI
Sector
Profitability FY 2025
$139.8M
$2.6M
Return on invested capital
-1579.24%
-32.91%
Return on assets
-160.51%
-29.56%
Return on equity
--
-38.66%
Earnings Date
Last Earnings Date
Feb
12
Next Earnings Date
May
11
Estimated Next Earnings Date
May
14
Balance Sheet
KPTI
Sector
Total cash
$63.7M
$25.2M
Short term investments
$46.2M
$24.1M
Total assets
$117.5M
$72.8M
Long term debt
$232.6M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
44
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
73
HYMC alert for Feb 19
Hycroft Mining Holding Corp. [HYMC] is up 3.81% over the past day.
Buy
57
GLBE alert for Feb 19
Global-e Online Ltd. [GLBE] is up 4.19% over the past day.
Sell
37
ACLS alert for Feb 19
Axcelis Technologies, Inc. [ACLS] is down 1.71% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
